Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Oliver Higuera"'
Autor:
F Arias-Lotto, Patricia Cruz, S Martinez-Recio, L Gutierrez-Sainz, M I Esteban-Rodriguez, R A Gonzalez, Oliver Higuera, J De Castro-Carpeño
Publikováno v:
Clinical and Translational Oncology. 23:2030-2035
Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, with a poor prognosis. MPM needs to find prognostic factors of survival. We provided the management of patients with MPM and sought to determine whether pre-treatment levels of deri
Autor:
Xabier Mielgo-Rubio, Oliver Higuera, Margarita Martín, Virginia Calvo, F. Hernando-Trancho, José Ramón Jarabo, Jordi Remon, Felipe Couñago, Esther Conde, Fernando Lopez-Rios, Javier de Castro, Javier Ras Luna, Mariano Provencio
Publikováno v:
Future oncology (London, England). 17(30)
Lung cancer continues to be the leading cause of cancer mortality and a serious health problem despite the numerous advances made in the last decade and the rapid advance of research in this field. In recent years, there has been a decrease in mortal
Autor:
Rodolfo Chicas-Sett, Gala Serrano Bermúdez, Anna Librán Oriol, Francisco Javier García Navalón, Oliver Higuera Gómez, Manuel Cobo Dols, Pedro Sánchez Mauriño, Alexandra Giraldo Marín, Pilar Torres, Ibone Huerta González, Almudena Sanz-Yagüe, Ignacio Delgado Mingorance, Jose L. Perez, Luis Cabezón-Gutiérrez, María Isabel Blancas López-Barajas, Carmen Beato Zambrano, Diana Moreno Muñoz, Begoña Soler López, Alfredo Paredes Lario
Publikováno v:
BMJ Supportive & Palliative Care. :bmjspcare-2020
ObjectivesNaloxegol is a peripherally acting µ-opioid receptor antagonist (PAMORA) for treatment of opioid-induced constipation (OIC). The main objective was to analyse the long-term efficacy, quality of life (QOL) and safety of naloxegol in patient
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Currently, pancreatic adenocarcinoma mainly occurs after 60 years of age, and its prognosis remains poor despite modest improvements in recent decades. The aging of the population will result in a rise in the incidence of pancreatic adenocarcinoma wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac18804dce9af477571e53dcea740205
https://hdl.handle.net/20.500.12530/27723
https://hdl.handle.net/20.500.12530/27723